Alex discusses the necessity of high drug prices to incentivize drug development, highlighting the importance of blockbuster drugs in the industry. The conversation shifts to the challenges of investing in prevention within healthcare systems, questioning the lack of focus on preventative treatments despite the potential benefits.
